A5004203950- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Immunodeficiency and Autoimmune Disorders
- Hemoglobinopathies and Related Disorders
- DNA Repair Mechanisms
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Immune Cell Function and Interaction
- Biomedical Ethics and Regulation
- Facial Nerve Paralysis Treatment and Research
- Viral-associated cancers and disorders
- Renal Transplantation Outcomes and Treatments
- Biomedical and Engineering Education
- Neuroblastoma Research and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Mesenchymal stem cell research
- Cardiac tumors and thrombi
- PARP inhibition in cancer therapy
- Histiocytic Disorders and Treatments
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders Research
Texas Children's Hospital
2021-2025
Baylor College of Medicine
2021-2025
Children's Cancer Center
2025
Houston Methodist
2023
Methodist Hospital
2023
Children's National
2019
George Washington University
2019
Masonic Cancer Center
2018
NHS Blood and Transplant
2017
Palmetto Hematology Oncology
2016
ABSTRACT Background Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR)‐modified T‐cell therapy, have shown efficacy in pediatric B‐cell acute lymphoblastic leukemia (B‐ALL) and are being investigated for other malignancies. A common toxicity associated with IEC therapy is cytokine release syndrome (CRS), which can lead to cardiovascular decompensation due systemic inflammation. Data limited regarding adverse effects children. This study aims describe the effect...
Abstract Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack virus-experienced donor cord blood (CB) prevented development ex vivo expanded donor-derived VSTs for recipients this source. Here we evaluated feasibility safety expansion CB from 20% fraction unit pediatric patients receiving a single (CBT). In 2 clinical trials conducted at separate sites, manufactured CB-derived multivirus-specific...
Childhood rhabdomyosarcoma (RMS) accounts for approximately 3.5% of cancer cases among children 0 to 14 years age. Genetic conditions associated with high risk childhood RMS include Li-Fraumeni syndrome, pleuropulmonary blastoma, Beckwith-Wiedemann and some RASopathies, such as neurofibromatosis type 1, Costello syndrome (CS), Noonan (NS). Here, we report the rare case a 4-year-old girl clinical features NS who developed an embryonal chest needed emergent treatment. Molecular genetic testing...
There is no consensus on the best donor for children with nonmalignant disorders and immune deficiencies in absence of a matched related (MRD). We evaluated 2-year overall survival (OS) after umbilical cord blood transplantation (UCBT) patients from 2009 to 2020 enrolled prospective clinical trial using either 5/6 or 6/6 UCB as cell source. Patients receive fully ablative busulfan, cyclophosphamide, fludarabine without serotherapy. Fifty-five were enrolled, median age 5 months (range, 1-111...
Abstract: Graft-versus-host disease (GVHD) continues to be a major complication following allogeneic hematopoietic cell transplantation (allo-HCT) with high morbidity and mortality. Corticosteroids are the first-line treatment for GVHD; however, substantial number of patients go on require second-line where no single therapeutic modality has been proven most effective. Extracorporeal photopheresis (ECP) is an efficient established therapy cutaneous T-cell lymphoma, GVHD, rejection after...
Men with type 2 diabetes are often characterized by abnormal plasma testosterone levels. This study was aimed at investigating whether treatment has an impact on cardiovascular risk factors in patients and late-onset hypogonadism (LOH), chronically treated hypoglycemic agents.This included 51 men diabetes, 26 of whom had already been metformin 25 glimepiride for least 6 months. On the basis patient preference, 15 receiving 12 were intramuscular enanthate (100 mg weekly) weeks. Plasma lipids,...
Abstract Introduction An HLA matched related donor (MRD) is the preferred source for performing a hematopoietic stem cell transplant (HSCT) in patients with severe combined immunodeficiency (SCID) (Heimall 2017). However, many lack an MRD and thus alternative donor, must be used. In these situations, umbilical cord blood (UCB) represents promising (Gragert 2014, Martinez 2022). Objectives The primary outcome of interest was one-year event free survival (EFS) secondary time to immunoglobulin...
While matched related donor (MRD) allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for transfusion-dependent beta-thalassemia (TDT), the use of alternative sources has increased, resulting in exploration novel transplant-conditioning regimens to reduce contribution graft-versus-host disease (GVHD) and graft failure (GF) transplant-related morbidity mortality. Alemtuzumab CD52 monoclonal antibody that been successfully incorporated into myeloablative conditioning...
Introduction: Immune effector cell (IEC) therapies including chimeric antigen receptor (CAR)-modified T-cell therapy have shown remarkable efficacy in relapsed/refractory pediatric B-acute lymphoblastic leukemia (B-ALL) and are being investigated for other hematological solid malignancies. The main toxicity is cytokine release syndrome (CRS), which can lead to cardiovascular decompensation. Data limited regarding the effects of IEC children, particularly non-B-ALL Methods: We retrospectively...